
FDA Mandates New Label Warnings for Buprenorphine and Methadone Over CNS Depressant Risks
FDA requires updated labeling for buprenorphine and methadone products, emphasizing that medication-assisted treatment should not be withheld from patients using benzodiazepines or other CNS depressants.






